The Ethics of Genetic Incidental Findings

Benjamin E. Berkman
NIH Department of Bioethics
November 13, 2019
Disclaimer

- The following presentation does not reflect the official views of the NHGRI, NIH, or DHHS.
Roadmap

- Background: next-generation sequencing
- Incidental findings in genetic research
- Unresolved ethical controversies and questions
Glossary of Terms/Acronyms

- GWAS = genome-wide association studies
- SNP = single nucleotide polymorphism
- dbGaP = database of Genotypes and Phenotypes
- WES = whole exome sequencing
- WGS = whole genome sequencing
- NGS = next generation sequencing
- IF = incidental findings
Definition

• An incidental result is:
  • “[A] finding concerning an individual research participant that has potential health or reproductive importance and is discovered in the course of conducting research but is beyond the aims of the study”

Warm-up Case

- A clinical researcher is studying the genetic etiology of breast cancer in a group of subjects that present for treatment at an academic medical center. After obtaining research-specific informed consent, the study team generates sequences data from surplus tumor tissue that had been removed for clinical purposes. They are interrogating the BRCA region to search for novel disease-associated variants. They propose to de-identify their sequence data, and do not plan to return any results. Although they are not searching for known disease-associated variants, it is likely that they will occasionally discover known BRCA variants that could be clinically relevant, particularly for near-term treatment decisions.
Facts

• The original research plans did not intend to inform prospective research participants of their individual research results.

• The relevant consent language read:
  • “You should not expect to get individual results from research done with your blood.”
Questions

• Would you approve this protocol as proposed? Why or why not?
The Incidental Findings Problem
• NGS is a powerful research tool
• Generates massive amounts of data about an individual, beyond that necessary to answer a scientific question
• Can include clinically relevant findings
• What ethical obligation do researchers have with regards to these findings?
En Route to Routine Whole-Genome Sequencing

- Targeted Genetic Research
- Whole ‘Exome’
- Whole Genome

Then  ↓  Now  ↓  Soon!

Time
Definitions

• Primary research findings
  • Results related to the condition under investigation

• Incidental findings
  • Results that are accidentally found in the course of research analyses
    • Can be research related, or not

• Secondary clinical findings
  • Results unrelated to the condition being investigated, but that are actively sought (e.g., ACMG list)
Early Views

• Focused on the type of information that could or should be returned
  • Net benefit (strong, possible, unlikely)
  • Clinical utility, personal utility, general utility
  • Relative risk > X
• “Stumble strategy”
• Little engagement about the kinds of research that should return findings
• Case by case analysis
A Decade Later

• Genomes are cheap (~$1000)

• Increasingly ubiquitous
  • 2003 – 1
  • 2015 – 50,000
  • 2018 – 1.5M

• Research is a large driver of this sequencing
  • UK Biobank + AOU = millions subjects
A Decade Later

- Increasing clinical utility
  - 75,000 genetic tests actively available
  - 5,210 new tests per year (2017) – 14.3 per day
  - 3% of FDA approved drugs have pharmacogenomic recommendations

- Improving quality and reliability
  - Regular increases in coverage/resolution of sequencing
A Decade Later

• Proliferation of expertise and guidance
  • e.g, ClinVar, gnomAD, ClinGen
  • Clinical molecular genetics - new area of expertise straddling pathology and medicine

• From dangerous to consistent and fairly well-established
  • Psychosocial risks seem to be minimal
  • Genomic information = medical information
Existing Guidance about Returning Research IFs
ACMG

“Minimum list” of incidental findings to report from any clinical sequence (n=59)
  
  “unequivocally pathogenic mutations in genes where pathogenic variants lead to disease with very high probability and where evidence strongly supports the benefits of early intervention”

- Variants on the list should be actively sought by the laboratory
  - “Opportunistic Screening”

- Limited to the clinical realm, but was sporadically transposed to the research setting
Existing ROR Guidance

- PCSBI, 2013
- The Floor, the Ceiling, and Everything in Between (Jarvik et al., 2014)
- ESHG, CCMG
- NIH intramural effort (Darnell et al., 2016)
- National Academies Science, 2018
- ASHG recontact guidance (Bombard et al., 2019)
Existing ROR Guidance

• Very high-level
  • Avoid making specific recommendations

• Deference to IRBs
  • Study-specific determinations

• Punt on controversial issues
Time for Specificity?

• Genomic sequencing is everywhere
• Set of genetic information that can help people keeps growing
• As a genomic SOC is established, the Wild West scattershot approach is increasingly unjustifiable
• Deference to IRBs leads to inconsistent and inequitable outcomes
Initial Views on Whether There is an Obligation to Disclose GIFs

Do you believe that researchers have an obligation to disclose genetic incidental findings to participants?

- Always 13%
- Sometimes 65%
- Rarely 13%
- Never 2%
- Don’t know 7%

Factors that can diminish an obligation to disclose GIFs

<table>
<thead>
<tr>
<th>Factor</th>
<th>Strongly agree or agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate clinical or analytic validity</td>
<td>71%</td>
</tr>
<tr>
<td>Inadequately demonstrated clinical utility</td>
<td>66%</td>
</tr>
<tr>
<td>Lack of funding, resources or infrastructure</td>
<td>29%</td>
</tr>
<tr>
<td>Adverse psychological impact</td>
<td>23%</td>
</tr>
<tr>
<td>Participants won’t understand</td>
<td>22%</td>
</tr>
<tr>
<td>Investigators ≠ clinicians</td>
<td>18%</td>
</tr>
<tr>
<td>Time and effort required</td>
<td>7%</td>
</tr>
</tbody>
</table>

#1 (validity) and #2 (utility) > #3, #4, #5, #6, #7 (p<0.05)
An Emerging View?

- Beneficence
  - Some genetic information can be very clinically important
- But research ≠ clinical care
  - Researchers cannot be responsible for the entire medical care of the subject
- Duty to rescue/ancillary care
Duty to Rescue

• General duty to rescue
  • Applies to everyone
  • Operative when
    • Benefit of rescue is very high
    • Burden of rescue is relatively low
Ancillary Care

- Ancillary care obligations are a related role-specific obligation for researchers
- "Ancillary care is that which goes beyond the requirements of scientific validity, safety, keeping promises, or rectifying injuries." (Belsky and Richardson)
- Situations where there is a significant need that the researcher is uniquely able to address at little cost to the research enterprise
Ancillary Care

• Incidental findings have been conceptually linked to ancillary care
  • General (Bredenoord; Ulrich; Beskow and Burke)
  • Partial entrustment model (Richardson)
  • Duty to look (Gliwa and Berkman; Savulescu)
  • IFs in low-resource settings (Sullivan and Berkman)
Ancillary Care

• Seems like a plausible model
  • Specifies conditions when results should be returned
  • Balances benefit to participant and burden to research enterprise

• But…
  • Makes ROR dependent on researcher expertise and protocol specific resources
    • Inefficient
    • Justice concerns
Institutional Duty of Easy Rescue

• Some have argued that the duty to rescue applies to institutions rather than individuals (Rulli and Millum; MacKay and Rulli; Garrett)
  • Limits scope of duty (to research subjects)
  • Provides framework to balance rescue obligations with institutional goals
• Related to a professional duty to rescue
My Initial Claim

• There is a broad but shallow obligation to return genetic results generated in research
  • Broad in the sense that it applies to most research protocols
  • Shallow in the sense that it employs a fairly high threshold for what information needs to be returned
My Initial Claim

• This obligation falls to the institution (e.g., NIAID, NIH) rather than individual researchers, because:
  • Individual researchers will often lack the right expertise to analyze and return non-primary (i.e., non-immunological) findings
  • A centralized resource can be created/expanded to more efficiently and effectively provide support to investigators
  • Creates a uniform policy that solves the fairness problem that plagues most institutions (intramurally and extramurally)
Are There Limits on the Scope of ROR Obligations?
Does this duty apply universally, or are there kinds of research where there is no duty to return results?

Professional duty to rescue

Richardson’s “partial entrustment model”
  - When subjects enroll in a study, they entrust limited aspects of their health to researchers
  - Ancillary care obligations only attach to “entrusted” aspects of health

Four cases
Case 1

- A medical geneticist wants to add WES to his existing natural history study of a rare genetic disease. This would include analyzing specimens that were already collected under this protocol.

- Subjects enrolled in the study have ongoing contact with the research team, participating in quarterly follow-up visits and receiving standard of care treatment as needed.

- The original consent describes genetic analysis and a general plan not to return incidental findings unless clinically relevant to the management of the disease being investigated.
Scope of Obligation – Case 1

• Patients seen at the Clinical Center by intramural investigators where there is a substantial clinical relationship, including sequencing
  • Clear broad entrustment of medical care and specific entrustment of genetic information
  • Definitely return
Case 2

- NIH investigators are collecting WGS and identifiable clinical data from populations in low-resource African countries. Based on experience with similar studies in the US, they propose to analyze the data for the ACMG list of 56 high-value incidental findings. Given the lack of health care resources available to their African participants, it is unlikely that they will be able to access treatment for any positive findings.
Scope of Obligation – Case 2

• International genetic research projects conducted by intramural investigators where there is a substantial clinical relationship, but when patients do not come to the CC
  • Similar to Case 1; clear entrustment
  • Default to return findings, just like for CC patients
Scope of Obligation – Case 2

• Caveat #1: First ask local representatives if returning results makes sense in their context
  • Consideration of unintended negative consequences in specific local contexts

• Caveat #2: Actionability problem
  • Solicit preferences about RNTK
Case 4

• An NIH researcher has identified a source of clinical samples from patients at a biobank.
• The samples were collected with written informed consent and IRB approval.
• The NIH researcher will have access to deidentified information about these patients.
• The NIH researcher wants to proceed with whole exome sequencing and set up a planning meeting with the sequencing center.
Scope of Obligation – Case 4

- Secondary research on deidentified samples/data not collected by NIH intramural researchers
  - No entrustment to secondary researchers, so no obligation to return findings (primary or secondary)
  - [Contra Richardson]
- Caveat: We want to discourage projects from deidentifying samples/data solely to avoid having to return results (i.e., only when there is a strong scientific justification for deidentification)
Case 3

• A bench scientist studying a common, complex disorder wants to initiate a protocol to collect samples prospectively for WES.

• The protocol involves a one-time blood draw. Subjects will be recruited from sites across the country.

• There is no ongoing clinical relationship between researcher and subjects (but assume that recontact is feasible).
Subjects seen by intramural investigators where there is only minimal contact (e.g., one-time blood draw) or research on identified secondary samples.

Even if one accepts the partial-entrustment model, it isn’t always obvious whether there has been sufficient entrustment in these marginal cases to derive an obligation to return.
Unresolved Controversies

• Legacy samples and reconsent
• Duty to look
• Returning results to relatives of deceased probands
• CLIA
  • Advances in clinical variant interpretation
  • Re-analysis and recontact
• Right not to know
The Right Not to Know?

DID MY GENETIC TESTS COME BACK?  
YEAH, SIT DOWN.  
IS IT BAD NEWS?  WHAT ARE MY RISK FACTORS?

WE CAN'T BE SURE ABOUT THIS, BUT WE'VE ANALYZED GENES ON SEVERAL OF YOUR CHROMOSOMES, AND IT'S HARD TO AVOID THE CONCLUSION:

AT SOME POINT, YOUR PARENTS HAD SEX.  
OH GOD!  
STAY CALM! IT'S POSSIBLE IT WAS JUST ONCE!  
I... I NEED TO BE ALONE.
A Case

- P is having her genome sequenced and during the informed consent process opts not to receive any incidental results. During their analysis, her physicians find evidence of high genetic risk for Hereditary Non-Polyposis Colon Cancer (HNPCC). They believe that this information will prevent serious disease and perhaps even save P’s life. Should they disclose the finding, even though P indicated that she did not want to receive any secondary findings.
Thank You!
Questions?